PRENETICS GLOBAL LTD-CL A (PRE) Stock Price, Quote, News and Overview
NASDAQ:PRE - Nasdaq - KYG722451229 - Common Stock - Currency: USD
PRE Quote, Performance and Key Statistics
NASDAQ:PRE (8/1/2025, 8:00:00 PM)
8
-0.07 (-0.87%)
The current stock price of PRE is 8 USD. In the past year, price increased by 48.15%.
PRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 9.85 | 79.03B | ||
| CI | THE CIGNA GROUP | 9.34 | 70.05B | ||
| LH | LABCORP HOLDINGS INC | 17.27 | 21.68B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.06 | 19.10B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.58 | 14.75B | ||
| HIMS | HIMS & HERS HEALTH INC | 90.65 | 14.00B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 94.81 | 12.38B | ||
| DVA | DAVITA INC | 14.99 | 10.46B | ||
| CHE | CHEMED CORP | 18.68 | 6.11B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.13B | ||
| OPCH | OPTION CARE HEALTH INC | 20.93 | 4.63B | ||
| CRVL | CORVEL CORP | 47.64 | 4.46B |
Related stock screener links
About PRE
Company Profile
Prenetics Global Limited is a health sciences company, which engages in the provision of early detection, prevention, and treatment of cancer. The company employs 320 full-time employees The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.
Company Info
PRENETICS GLOBAL LTD-CL A
Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
Hong Kong HM 08 HK
CEO: David Zwiener
Employees: 320
Phone: 85222109588
PRENETICS GLOBAL LTD-CL A / PRE FAQ
What is the stock price of PRENETICS GLOBAL LTD-CL A today?
The current stock price of PRE is 8 USD. The price decreased by -0.87% in the last trading session.
What is the ticker symbol for PRENETICS GLOBAL LTD-CL A stock?
The exchange symbol of PRENETICS GLOBAL LTD-CL A is PRE and it is listed on the Nasdaq exchange.
On which exchange is PRE stock listed?
PRE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PRENETICS GLOBAL LTD-CL A stock?
5 analysts have analysed PRE and the average price target is 14.28 USD. This implies a price increase of 78.5% is expected in the next year compared to the current price of 8. Check the PRENETICS GLOBAL LTD-CL A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PRENETICS GLOBAL LTD-CL A worth?
PRENETICS GLOBAL LTD-CL A (PRE) has a market capitalization of 104.24M USD. This makes PRE a Micro Cap stock.
How many employees does PRENETICS GLOBAL LTD-CL A have?
PRENETICS GLOBAL LTD-CL A (PRE) currently has 320 employees.
What are the support and resistance levels for PRENETICS GLOBAL LTD-CL A (PRE) stock?
PRENETICS GLOBAL LTD-CL A (PRE) has a support level at 7.88 and a resistance level at 8.07. Check the full technical report for a detailed analysis of PRE support and resistance levels.
Is PRENETICS GLOBAL LTD-CL A (PRE) expected to grow?
The Revenue of PRENETICS GLOBAL LTD-CL A (PRE) is expected to decline by -56.61% in the next year. Check the estimates tab for more information on the PRE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRENETICS GLOBAL LTD-CL A (PRE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRE, evaluating the profitability, health, valuation and growth aspects
- PRENETICS GLOBAL LTD-CL A (PRE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRENETICS GLOBAL LTD-CL A (PRE) Sales and EPS estimates to see what analysts future expectations are.
- PRENETICS GLOBAL LTD-CL A (PRE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRENETICS GLOBAL LTD-CL A (PRE) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRENETICS GLOBAL LTD-CL A (PRE) Stock Chart to make your own analysis
- PRENETICS GLOBAL LTD-CL A (PRE) Latest news and press-releases to stay up to date.
Does PRENETICS GLOBAL LTD-CL A (PRE) stock pay dividends?
PRE does not pay a dividend.
When does PRENETICS GLOBAL LTD-CL A (PRE) report earnings?
PRENETICS GLOBAL LTD-CL A (PRE) will report earnings on 2025-10-06, before the market open.
What is the Price/Earnings (PE) ratio of PRENETICS GLOBAL LTD-CL A (PRE)?
PRENETICS GLOBAL LTD-CL A (PRE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.8).
What is the Short Interest ratio of PRENETICS GLOBAL LTD-CL A (PRE) stock?
The outstanding short interest for PRENETICS GLOBAL LTD-CL A (PRE) is 0.46% of its float. Check the ownership tab for more information on the PRE short interest.
PRE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRE. When comparing the yearly performance of all stocks, PRE is one of the better performing stocks in the market, outperforming 92.59% of all stocks.
PRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRE. PRE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRE Financial Highlights
Over the last trailing twelve months PRE reported a non-GAAP Earnings per Share(EPS) of -3.8. The EPS increased by 85.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.5% | ||
| ROE | -31.41% | ||
| Debt/Equity | 0 |
PRE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to PRE. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 20.64% and a revenue growth -56.61% for PRE